市場調查報告書

Fondaparinux的全球市場:2020-2026年

Global Fondaparinux Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 949665
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
Fondaparinux的全球市場:2020-2026年 Global Fondaparinux Market 2020-2026
出版日期: 2020年06月27日內容資訊: 英文
簡介

預防血栓症的抗凝固藥的Fondaparinux的市場在預測期間內預計大幅度成長。深部靜脈血栓症(DVT)的盛行率大幅度擴大,老年人口增加等要素促進該市場的成長。老年人口的增加是骨質疏鬆症的盛行率增加的主要原因之一,也是髖關節及膝關節置換術的需求提高的要素。

本報告提供全球Fondaparinux的市場調查,市場定義和概要,市場成長的各種影響因素分析,相關法律,市場規模的變化、預測,產品類型等各種區分的明細,地區、各主要國家的詳細分析,競爭環境,企業佔有率,主要企業簡介等資訊彙整。

第1章 報告概要

第2章 市場概要、考察

  • 調查範圍
  • 分析師的見解、目前市場趨勢
  • 法律規章

第3章 競爭情形

  • 企業佔有率分析
  • 主要策略分析
  • 主要企業分析

第4章 市場影響因素

  • 成長推動因素
  • 阻礙成長要素
  • 市場機會

第5章 市場分析、預測:各種區分

  • 各產品類型
    • 品牌藥
    • 學名藥

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章 企業簡介

  • Apicore LLC
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd. (CHL)
  • Dr Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Italfarmaco S.p.A.
  • Mylan N.V.
  • Sandoz International GmbH
  • ScinoPharm Taiwan, Ltd.
目錄
Product Code: OMR2021984

Global Fondaparinux Market Size, Share & Trends Analysis Report, By Product Type (Branded and Generics) and Forecast, 2020-2026

The global fondaparinux market is estimated to grow significantly during the forecast period. The major factors contributing to the market growth include a significant rise in the prevalence of deep vein thrombosis (DVT) and rising geriatric population. As per the United Nations (UN), by 2050, 1 in 6 people globally will be more than the age of 65, increased from 1 in 11 in 2019. In 2019, 703 million people were aged 65 years or over globally, which is expected to double to 1.5 billion in 2050. Increasing geriatric population is one of the major causes for an increase prevalence of osteoporosis, which results in the emerging demand for hip and knee replacement procedures. This contributes to the rising adoption of fondaparinux to prevent venous thromboembolic events (VTE) in patients who are undergoing orthopedic surgeries of the lower limbs including hip replacement surgery, hip fracture, and knee surgery. Fondaparinux works by blocking the activity of some clotting substances in the blood. It is being significantly used owing to the longer half-life and high efficiency than heparin.

Geographically, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America is expected to hold a significant share in the market owing to the rising number of hip and knee replacement procedures in the region. In 2015, 57,673 hip primary replacement were performed by 2,572 surgeons in the US and 87,593 primary knee replacement procedures were performed by 2,281 surgeons in the country. These procedures are rising significantly owing to the rising prevalence of orthopedic conditions in the country, which in turn, contributes to the adoption of fondaparinux to prevent blood clot after the hip and knee replacement procedure.

Some key players in the market include Mylan N.V., GlaxoSmithKline plc, Dr. Reddy's Laboratories, Inc., Aurobindo Pharma Ltd., and Cadila Healthcare Ltd. (CHL). The strategies adopted by the market player include mergers and acquisitions and product launches to expand market share and gain a competitive advantage. For instance, in December 2017, Aurobindo Pharma Ltd. gained the US FDA approval for production and marketing of its generic version of Fondaparinux sodium injection, 2.5mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL single-dose prefilled syringes, for the prevention of DVT. The approved ANDA is a therapeutically equivalent and bioequivalent to the reference listed drug (RLD) product Arixtra Injection of Mylan Ireland. The product was introduced in January 2018.

Research Methodology

The market study of the global fondaparinux market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Fondaparinux Market Research and Analysis by Product Type

The Report Covers:

  • Comprehensive research methodology of the global fondaparinux market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global fondaparinux market.
  • Insights about market determinants, which are stimulating the global fondaparinux market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Mylan N.V.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. GlaxoSmithKline plc
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Dr. Reddy's Laboratories, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Aurobindo Pharma Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Cadila Healthcare Ltd. (CHL)
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Fondaparinux Market by Product Type
    • 5.1.1. Branded
    • 5.1.2. Generics

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Apicore LLC
  • 7.2. Aurobindo Pharma Ltd.
  • 7.3. Cadila Healthcare Ltd. (CHL)
  • 7.4. Dr Reddy's Laboratories Ltd.
  • 7.5. GlaxoSmithKline plc
  • 7.6. Italfarmaco S.p.A.
  • 7.7. Mylan N.V.
  • 7.8. Sandoz International GmbH
  • 7.9. ScinoPharm Taiwan, Ltd.

LIST OF TABLES

  • 1. GLOBAL FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL BRANDED FONDAPARINUX DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL GENERICS FONDAPARINUX DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 5. NORTH AMERICAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 6. NORTH AMERICAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 7. EUROPEAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 8. EUROPEAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 9. ASIA-PACIFIC FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 10. ASIA-PACIFIC FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 11. REST OF THE WORLD FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL FONDAPARINUX MARKET SHARE BY PRODUCT TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL FONDAPARINUX MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 3. US FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF THE WORLD FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)